Bullboard Post History

by PeptidePete

Order by:

V.ARCH	Potential New Treatment for AKI marks 200 days of dosing {^youtubevideo\|(width)425\|(height)264\|(rel)False\|(url)https://www.youtube.com... September 23, 2024
V.ARCH	Dosing of Key Inflammation pathway marked 200 days Learn more about LSALT Peptide and those who developed it here. September 23, 2024
V.ARCH	Cilastatin, new therapeutic promise for acute kidney injury Cilastatin, a New Therapeutic Promise for Acute Kidney Injury September 21, 2024
V.ARCH	Why do Phase II trials fail? Failures in phase II testing overall usually occur because: 1) previously... September 17, 2024
V.ARCH	Expanding Phase II AKI Trial - Alberta Dosing Approved University of Calgary Cumming School of Medicine Approved by AHS September 12, 2024
V.ARCH	Great Management - Grant Saves Shareholder Dilution Again!! The recent PONTIAC trial grant saves shareholders 1,268,000 shares in... August 5, 2024
V.ARCH	Another Free Phase II Trial The PONTIAC clinical team of investigators was awarded $1,500,000 by the... August 5, 2024
V.ARCH	GMP Glass vial stage for Cilastatin Over the next several weeks Dalton will be completing the quality control... July 28, 2024
V.ARCH	Health Canada Approved - Canadian Hospitals Joining In 3 Study Locations Cumming School of Medicine Unity Health Toronto... July 28, 2024
V.ARCH	Turkey Ministry of Health is recruiting to stop AKI 6 Study Locations Gazi University Istanbul University Kosuyolu... July 28, 2024
V.ARCH	New Mechanism - Decreasing Biomarkers "Collectively, a greater proportion of the biomarkers decreased from... July 28, 2024
V.ARCH	The LSALT study currently has 9 locations July 28, 2024
V.ARCH	10 Best Canadian Biotech Stocks - Article 1) Bellus Health 2) Finnec Pharma 3) Sernova Corp 4) Arch... July 27, 2024
V.ARCH	Arch Biopartners 2025 TSX Venture 50 Time Will Tell July 27, 2024
V.ARCH	Arch Biopartners 2022 TSX Venture 50 {^youtubevideo\|(width)425\|(height)264\|(rel)False\|(url)https://www.youtube.com... July 27, 2024
V.ARCH	Arch Biopartners 2019 TSX Venture 50 {^youtubevideo\|(width)425\|(height)264\|(rel)False\|(url)https://www.youtube.com... July 27, 2024
V.ARCH	Chronic Disease - Yes Please Since July 2021 the Canaidan Institutes of Health Research granted Arch... July 27, 2024
V.ARCH	Antibody Anybody In June 2021 Arch filed a new Patent application for novel Antibody... July 27, 2024
V.ARCH	RE:Drug Repurposing inbound? Systematic review potential ? Pontiac: Prevention of Nephrotoxin-induced AKI with Cilastatin Trial Award :... July 27, 2024
V.ARCH	Drug Repurposing inbound? Systematic review potential ? In April 2021 Arch Biopartners entered into worldwide License Agreement... July 27, 2024

Become a member today, It's free!

Bullboard Post History

by PeptidePete

Potential New Treatment for AKI marks 200 days of dosing

Dosing of Key Inflammation pathway marked 200 days

Cilastatin, new therapeutic promise for acute kidney injury

Why do Phase II trials fail?

Expanding Phase II AKI Trial - Alberta Dosing Approved

Great Management - Grant Saves Shareholder Dilution Again!!

Another Free Phase II Trial

GMP Glass vial stage for Cilastatin

Health Canada Approved - Canadian Hospitals Joining In

Turkey Ministry of Health is recruiting to stop AKI

New Mechanism - Decreasing Biomarkers

The LSALT study currently has 9 locations

10 Best Canadian Biotech Stocks - Article

Arch Biopartners 2025 TSX Venture 50

Arch Biopartners 2022 TSX Venture 50

Arch Biopartners 2019 TSX Venture 50

Chronic Disease - Yes Please

Antibody Anybody

RE:Drug Repurposing inbound? Systematic review potential ?

Drug Repurposing inbound? Systematic review potential ?

Featured Company

Forsys Metals Corp T.FSY

Become a member today, It's free!

Sign In

Send my password

Become a member today, It's free!

Bullboard Post History

by PeptidePete

Featured Company